TNC and glioblastoma: Furthermore, radiolabelled preparations of monoclonal antibodies specific to the A1 or the D domain of tenascin-C have been investigated for the radioimmunotherapy of patients with glioblastoma (Riva et al, 2000; Paganelli et al, 2006; Zalutsky et al, 2007, 2008).